Bartra C, Irisarri A, Villoslada A, Corpas R, Aguirre S, Garcia-Lara E, Sunol C, Pallas M, Grinan-Ferre C, Sanfeliu C (2022) <br />Neuroprotective Epigenetic Changes Induced by Maternal Treatment with an Inhibitor of Soluble Epoxide Hydrolase Prevents Early Alzheimer's Disease Neurodegeneration<br /><i>Int J Mol Sci</i> <b>23</b>: <br /><br />Codony S, Pont C, Grinan-Ferre C, Di Pede-Mattatelli A, Calvo-Tusell C, Feixas F, Osuna S, Jarne-Ferrer J, Naldi M, Bartolini M, Loza MI, Brea J, Perez B, Bartra C, Sanfeliu C, Juarez-Jimenez J, Morisseau C, Hammock BD, Pallas M, Vazquez S, Munoz-Torrero D (2022) <br />Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease<br /><i>Journal of Medicinal Chemistry</i> <b>65</b>: 4909<br /><br />Codony S, Entrena JM, Calvo-Tusell C, Jora B, Gonzalez-Cano R, Osuna S, Corpas R, Morisseau C, Perez B, Barniol-Xicota M, Grinan-Ferre C, Perez C, Rodriguez-Franco MI, Martinez AL, Loza MI, Pallas M, Verhelst SHL, Sanfeliu C, Feixas F, Hammock BD, Brea J, Cobos EJ, Vazquez S (2022) <br />Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors<br /><i>Journal of Medicinal Chemistry</i> <b>65</b>: 13660<br /><br />Jarne-Ferrer J, Grinan-Ferre C, Bellver-Sanchis A, Vazquez S, Munoz-Torrero D, Pallas M (2022) <br />A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer's Disease Mice Models<br /><i>Pharmaceuticals (Basel)</i> <b>15</b>: <br /><br />Codony S, Calvo-Tusell C, Valverde E, Osuna S, Morisseau C, Loza MI, Brea J, Perez C, Rodriguez-Franco MI, Pizarro-Delgado J, Corpas R, Grinan-Ferre C, Pallas M, Sanfeliu C, Vazquez-Carrera M, Hammock BD, Feixas F, Vazquez S (2021) <br />From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis<br /><i>Journal of Medicinal Chemistry</i> <br /><br />Grinan-Ferre C, Companys-Alemany J, Jarne-Ferrer J, Codony S, Gonzalez-Castillo C, Ortuno-Sahagun D, Vilageliu L, Grinberg D, Vazquez S, Pallas M (2021) <br />Inhibition of Soluble Epoxide Hydrolase Ameliorates Phenotype and Cognitive Abilities in a Murine Model of Niemann Pick Type C Disease<br /><i>Int J Mol Sci</i> <b>22</b>: <br /><br />Pont C, Ginex T, Grinan-Ferre C, Scheiner M, Mattellone A, Martinez N, Arce EM, Soriano-Fernandez Y, Naldi M, De Simone A, Barenys M, Gomez-Catalan J, Perez B, Sabate R, Andrisano V, Loza MI, Brea J, Bartolini M, Bolognesi ML, Decker M, Pallas M, Luque FJ, Munoz-Torrero D (2021) <br />From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects<br /><i>Eur Journal of Medicinal Chemistry</i> <b>225</b>: 113779<br /><br />Vasilopoulou F, Rodriguez-Arevalo S, Bagan A, Escolano C, Grinan-Ferre C, Pallas M (2021) <br />Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: A Comparative study with donepezil<br /><i>British Journal of Pharmacology</i> <br /><br />Grinan-Ferre C, Codony S, Pujol E, Yang J, Leiva R, Escolano C, Puigoriol-Illamola D, Companys-Alemany J, Corpas R, Sanfeliu C, Perez B, Loza MI, Brea J, Morisseau C, Hammock BD, Vazquez S, Pallas M, Galdeano C (2020) <br />Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease<br /><i>Neurotherapeutics</i> <br /><br />Pallas M, Vazquez S, Sanfeliu C, Galdeano C, Grinan-Ferre C (2020) <br />Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy<br /><i>Biomolecules</i> <b>10</b>: <br /><br />Perez-Areales FJ, Garrido M, Aso E, Bartolini M, De Simone A, Espargaro A, Ginex T, Sabate R, Perez B, Andrisano V, Puigoriol-Illamola D, Pallas M, Luque FJ, Loza MI, Brea J, Ferrer I, Ciruela F, Messeguer A, Munoz-Torrero D (2020) <br />Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6<br /><i>Journal of Medicinal Chemistry</i> <b>63</b>: 9360<br /><br />Viayna E, Gomez T, Galdeano C, Ramirez L, Ratia M, Badia A, Clos MV, Verdaguer E, Junyent F, Camins A, Pallas M, Bartolini M, Mancini F, Andrisano V, Arce MP, Rodriguez-Franco MI, Bidon-Chanal A, Luque FJ, Camps P, Munoz-Torrero D (2010) <br />Novel huprine derivatives with inhibitory activity toward beta-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates<br /><i>ChemMedChem</i> <b>5</b>: 1855<br /><br />Camps P, Formosa X, Galdeano C, Gomez T, Munoz-Torrero D, Scarpellini M, Viayna E, Badia A, Clos MV, Camins A, Pallas M, Bartolini M, Mancini F, Andrisano V, Estelrich J, Lizondo M, Bidon-Chanal A, Luque FJ (2008) <br />Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation<br /><i>Journal of Medicinal Chemistry</i> <b>51</b>: 3588<br /><br />Jorda EG, Verdaguer E, Jimenez A, Canudas AM, Rimbau V, Camps P, Munoz-Torrero D, Camins A, Pallas M (2004) <br />(+/-)-huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration<br /><i>J Alzheimers Dis</i> <b>6</b>: 577<br /><br />